Parvus Therapeutics Inc

📍 South San Francisco, United States👥 20 employees💰 Last funded Oct 2017
Biotechnology Research🌐 parvustx.com
Website LinkedIn
Parvus Therapeutics Inc. is a privately held biopharmaceutical company developing Navacims™, a platform technology based on foundational research published in 2016 (Nature 530:434), to treat autoimmune diseases. Parvus’ mission is to shift the treatment paradigm toward Navacim-directed immune regulation, avoiding non-specific immune suppression associated with current therapies. Parvus’ innovative approach has the potential to benefit millions of patients suffering from debilitating autoimmune diseases and other chronic inflammatory conditions. Parvus is advancing a pipeline of proprietary drug candidates for multiple autoimmune indications through preclinical development and into the clinical. Parvus’ leadership team is experienced in successful drug discovery, development, manufacturing, regulatory approval, and commercialization.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Parvus Therapeutics Inc?
Parvus Therapeutics Inc has 1 investors on record on gritt.io.
When did Parvus Therapeutics Inc last raise funding?
The most recent investment in Parvus Therapeutics Inc recorded on gritt.io was in October 2017.
What industry is Parvus Therapeutics Inc in?
Parvus Therapeutics Inc operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Parvus Therapeutics Inc based?
Parvus Therapeutics Inc is headquartered in South San Francisco, United States.